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SObjective: A predicted postoperative (ppo) forced expiratory volume in 1 second (FEV1%) or diffusing capac-
ity of the lung for carbon monoxide (DLCO%) of<40% has traditionally been considered to convey a high risk
of lobectomy owing to elevated postoperative morbidity and mortality. These recommendations, however, were
largely derived from the pre–video-assisted thoracoscopic surgical (VATS) era. We hypothesized that VATS lo-
bectomy would be associated with acceptable morbidity and mortality at ppoFEV1% and ppoDLCO%
values<40%.
Methods: PpoFEV1% and ppoDLCO% were calculated for patients undergoing open or VATS lobectomy for
lung cancer in the Society of Thoracic Surgeons General Thoracic database from 2009 to 2011. Univariate com-
parisons, multivariate analyses, and 1:1 propensity matching were performed.
Results:A total of 13,376 patients underwent lobectomy (50.9% open, 49.1%VATS). A decreased ppoFEV1%
and ppoDLCO%were each independent predictors for both cardiopulmonary complications andmortality in the
open group (all P  .008). In the VATS group, ppoFEV1% was an independent predictor of complications
(P ¼ .001) but not mortality (P ¼ .77), and ppoDLCO% was an independent predictor of complications
(P¼ .046) and mortality (P¼ .008). With decreasing ppoFEV1% or ppoDLCO%, complications and mortality
increased at a greater rate in the open lobectomy than in a propensity-matched VATS group (n¼ 4215 each). For
patients with ppoFEV1%<40%, mortality was greater in the open (4.8%) than in the matched VATS group
(0.7%, P ¼ .003). Similar results were seen for ppoDLCO%< 40% (5.2% open, 2.0% VATS, P ¼ .003).
The rate of complications was significantly greater at ppoFEV1%< 40% in the open (21.9%) than in the
matched VATS (12.8%, P ¼ .005) group and similar results were seen with ppoDLCO%< 40% (14.9%
open, 10.4% VATS, P ¼ .016).
Conclusions: VATS lobectomy can be performed with acceptable rates of morbidity and mortality in patients
with reduced ppoFEV1% or ppoDLCO%. (J Thorac Cardiovasc Surg 2014;148:19-29)Supplemental material is available online.e Department of Cardiothoracic Surgery,a Stanford University School of
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The Journal of Thoracic and CLobectomy is the optimal treatment of early-stage lung
cancer.1,2 Patients considered for lobectomy often have
existing pulmonary disease, and pulmonary function
tests have become a cornerstone in the preoperative
physiologic assessment of those evaluated for surgical
resection. The forced expiratory volume in 1 second
(FEV1) and diffusing capacity of the lung for carbon
monoxide (DLCO) are the most commonly used
pulmonary function tests, and their values have correlated
inversely with postoperative mortality, complications, and
respiratory failure after pulmonary resection.3-12
FEV1 and DLCO readouts have been considered as
absolute values (eg, in expired volume for FEV1) and as a
‘‘percentage of predicted’’ value that has been normalized
to population data for age, gender, height, and race. The
use of the percentage of predicted FEV1 (FEV1%) and per-
centage of predicted DLCO (DLCO%) prevents bias
against older patients, women, and those of small stature.
FEV1% and DLCO% have been shown to correlate moreardiovascular Surgery c Volume 148, Number 1 19
Abbreviations and Acronyms
DLCO ¼ diffusing capacity of the lung for carbon
monoxide
DLCO% ¼ percentage of predicted DLCO
FEV1 ¼ forced expiratory volume in 1 second
FEV1% ¼ percentage of predicted FEV1
ppo ¼ predicted postoperative
VATS ¼ video-assisted thoracoscopic surgical
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Saccurately with postoperative morbidity and mortality than
do their absolute values.9
FEV1% and DLCO% have been further refined to pre-
dicted postoperative (ppo) parameters of FEV1%
(ppoFEV1%) and DCLO% (ppoDLCO%). These are
values calculated preoperatively to estimate the degree of
lung function that will remain after pulmonary resection.
Ppo values have been suggested to more accurately stratify
postoperative risk by normalizing to the extent of resection.
For instance, these parameters take into consideration the
differing amount of functional lung parenchyma that would
remain after sublobar resection, lobectomy, or pneumonec-
tomy. This approach can be useful in lobectomy candidates,
in that a variable amount of lung parenchyma will
remain after resection, depending on which lobe has
been resected. In this regard, several investigators have
demonstrated stronger relationships between ppoFEV1%
and ppoDLCO% and postoperative risk after pulmonary
resection compared with their parent FEV1% and DLCO%
values.7,8,10-12 Such comparisons have not, however,
been analyzed using data from a large multi-
institutional database.
ppoFEV1% and ppoDLCO% values of<40% of normal
have traditionally been thought to indicate an increased
operative risk for patients undergoing lobectomy.
This impression has been derived mostly from single-
institution data, relatively small patient cohorts, and
populations that often included patients undergoing
pneumonectomy (reviewed by Colice and colleagues3). In
contrast, others have reported successful lung cancer
resection in patients with severely reduced postoperative
predicted lung function, with reasonable rates of
morbidity and mortality.13-16 The study populations in
these reports, however, generally included a range of
pulmonary resections, spanning sublobar resection to
pneumonectomy.
It has become increasingly evident that video-assisted
thoracoscopic surgical (VATS) lobectomy has an advantage
over thoracotomy with regard to postoperative morbidity.
Compared with matched patients undergoing thoracotomy
and lobectomy, VATS lobectomy had a lower incidence of
arrhythmia, reintubation, and blood transfusion.17,18 An
open surgical approach has also been shown to be an20 The Journal of Thoracic and Cardiovascular Surgeindependent predictor of pulmonary complications, when
compared with VATS.19 Differences in postoperative mor-
tality between VATS and open lobectomy have been more
difficult to show, perhaps because of the overall small num-
ber of events.
We therefore set out to crystallize the utility of
ppoFEV1% and ppoDLCO% in the prediction of
postoperative cardiopulmonary complications and mortal-
ity in patients undergoing lobectomy for lung cancer, by
the VATS and the open approach, using a multi-institution
national general thoracic surgery database.
METHODS
The Society of Thoracic Surgeons General Thoracic Database
(version 2.081, representing 2009 to 2011) was queried to identify a cohort
of patients undergoing lobectomy for lung cancer in which ppoFEV1% and
ppoDLCO% could be calculated. This required availability of data for
FEV1% and DLCO%, laterality of the primary surgical procedure, and
lobe resected (categories of disease including lung cancer, upper lobe
[code 162.3], lung cancer, middle lobe [code 162.4], or lung cancer, lower
lobe [code 162.5]). Because the coding nomenclature in version 2.081 of
the database clusters VATS lobectomies and segmentectomies under a
single designation (Common Procedural Terminology code 32663),
segmentectomies and lobectomies were analyzed as a combined group in
both the open and VATS cohorts. For reference, the rates of segmentectomy
in the previous version of the database (version 2.07) were similar (open,
6.5%; VATS, 8%).20 Patients undergoing sleeve lobectomy were inten-
tionally excluded.
ppoFEV1% and ppoDLCO% were derived using the anatomic
method in which preoperative FEV1% or DLCO% is multiplied by
the fraction of the functional lung segments expected to remain after
lobectomy. The ppoFEV1% values were calculated using the equation
ppoFEV1% ¼ measured FEV1% 3 (19  number of segments re-
sected)/19. The number of segments resected was assigned as 3 for right
upper lobectomy, 2 for middle lobectomy, 5 for right lower lobectomy,
5 for left upper lobectomy, and 4 for left lower lobectomy.4,11,19,20 The
ppoDLCO% was calculated in a similar manner.
Mortality was defined as death within 30 days or before discharge after
lobectomy. Cardiopulmonary complications were considered any of
the following: atelectasis requiring bronchoscopy, pneumonia, adult
respiratory distress syndrome, bronchopleural fistula, pulmonary embolus,
initial ventilator support>48 hours, reintubation, tracheostomy, ventricular
arrhythmia requiring treatment, and myocardial infarction.
Statistical analyses were approved through the Society of Thoracic
Surgeons General Thoracic Database committee and performed as part
of a contracted agreement with the Duke Clinical Research Institute.
Comparisons of the preoperative characteristics between the groups were
performed using the 2-sample nonparametric Wilcoxon test for continuous
variables and the Fisher exact test for categorical variables. To identify
correlates of cardiopulmonary complications and mortality, generalized
mixed regression models with logit link and binomial error were
considered separately for the open and VATS lobectomy cohorts. Hospital
(participant) was considered as a random effect. When developing the
multivariable models, we first considered univariable regressions to
evaluate the univariable associations of each variable in Table 1 with
each outcome. The multivariable analysis initially considered variables
with a univariable P value< .10. Final models were created by manual
backward selection with confirmatory forward selection, and variables
with P<.05 were retained. The variables of primary interest, ppoFEV1%
and ppoDLCO%, were added last to the developed models to evaluate their
incremental value. Generalized mixed models were fit with the Statistical
Analysis Systems, version 9.3, statistical software (SAS Institute, Cary,ry c July 2014
TABLE 1. Preoperative variables of 13,736 patients undergoing lobectomy for lung cancer
Variable Total (n ¼ 13,376) Open (n ¼ 6802) VATS (n ¼ 6574) P value*
Age (y) 66.9  10.3 66.6  10.4 67.2  10.2 .001
Female gender 7151 (53.5) 3468 (51.0) 3683 (56.0) <.001
Race .029
White 11886 (89.0) 6031 (88.8) 5855 (89.3)
Black 1138 (8.5) 614 (9.0) 524 (8.0)
Asian 300 (2.2) 134 (2.0) 166 (2.5)
Other 31 (0.2) 16 (0.2) 15 (0.2)
BMI (kg/m2) 27.5  6.1 27.8  6.3 27.3  5.9 <.001
FEV1% 81.7  20.4 79.9  19.8 83.6  20.8 <.001
DLCO% 73.0  21.7 71.4  21.4 74.7  21.8 <.001
ppoFEV1% 64.6  16.7 63.1  16.3 66.2  17.0 <.001
ppoDLCO% 57.8  17.6 56.4  17.4 59.2  17.7 <.001
Smoking .002
Current 3394 (25.4) 1804 (26.5) 1590 (24.2)
Never or past 9977 (74.6) 4996 (73.5) 4981 (75.8)
Zubrod score <.001
0 5584 (41.8) 2499 (36.8) 3085 (46.9)
1 7191 (53.8) 3974 (58.4) 3217 (49.0)
2 511 (3.8) 276 (4.1) 235 (3.6)
3 79 (0.6) 48 (0.7) 31 (0.5)
4 5 (0.0) 3 (0.0) 2 (0.0)
5 1 (0.0) 0 (0.0) 1 (0.0)
ASA risk class <.001
I 54 (0.4) 24 (0.4) 30 (0.5)
II 2056 (15.4) 872 (12.8) 1184 (18.0)
III 9996 (74.7) 5066 (74.5) 4930 (75.0)
IV 1266 (9.5) 839 (12.3) 427 (6.5)
cT descriptor <.001
T1 7951 (61.3) 3554 (53.9) 4397 (69.0)
T2 3926 (30.3) 2295 (34.8) 1631 (25.6)
T3 868 (6.7) 601 (9.1) 267 (4.2)
T4 223 (1.7) 145 (2.2) 78 (1.2)
cN descriptor <.001
N0 11165 (86.1) 5409 (82.0) 5756 (90.3)
N1 1075 (8.3) 692 (10.5) 383 (6.0)
N2 692 (5.3) 480 (7.3) 212 (3.3)
N3 39 (0.3) 19 (0.3) 20 (0.3)
Preoperative chemotherapy 1258 (9.6) 884 (13.3) 374 (5.8) <.001
Preoperative RT 1043 (7.9) 714 (10.7) 329 (5.0) <.001
CAD 2879 (21.8) 1517 (22.7) 1362 (20.9) .012
CHF 383 (2.9) 194 (2.9) 189 (2.9) 1.0
PVD 1337 (10.1) 713 (10.7) 624 (9.6) .038
CVD 1069 (8.1) 584 (8.8) 485 (7.5) .006
HTN 8173 (61.7) 4144 (61.8) 4029 (61.7) .91
COPD 4664 (35.5) 2476 (37.2) 2188 (33.7) <.001
Diabetes 2445 (18.5) 1355 (20.3) 1090 (16.7) <.001
Last creatinine (mg/dL) 1.0  0.6 1.0  0.6 1.0  0.6 .16
Last hemoglobin (g/dL) 13.1  1.6 13.0  1.7 13.3  1.6 <.001
Steroid use 449 (3.4) 262 (3.9) 187 (2.9) .001
General thoracic reoperation 710 (5.4) 433 (6.5) 277 (4.2) <.001
Data presented as mean  standard deviation or n (%). VATS, Video-assisted thoracoscopic surgical; BMI, body mass index; FEV1%, percentage of predicted forced expiratory
volume in 1 second; DLCO%, percentage of predicted diffusing capacity of the lung for carbon monoxide; ppo, predicted postoperative; ASA, American Society of Anesthe-
siologists; cT, clinical T; cN, clinical N; RT, radiotherapy; CAD, coronary artery disease; CHF, congestive heart failure; PVD, peripheral vascular disease; CVD, cerebrovascular
disease; HTN, hypertension; COPD, chronic obstructive pulmonary disease. *Comparison between open and VATS groups.
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TABLE 2. Rates of cardiopulmonary complications and postoperative mortality in 13,376 patients undergoing lobectomy for lung cancer
Event Total (n ¼ 13,376) Open (n ¼ 6802) VATS (n ¼ 6574) P value*
Atelectasis requiring bronchoscopy 581 (4.3) 397 (5.8) 184 (2.8) <.001
Pneumonia 580 (4.3) 376 (5.5) 204 (3.1) <.001
ARDS 117 (0.9) 82 (1.2) 35 (0.5) <.001
Bronchopleural fistula 50 (0.4) 32 (0.5) 18 (0.3) .066
Pulmonary embolus 51 (0.4) 35 (0.5) 16 (0.2) .011
Ventilator support>48 h 101 (0.8) 69 (1.0) 32 (0.5) <.001
Reintubation 511 (3.8) 362 (5.3) 149 (2.3) <.001
Tracheostomy 164 (1.2) 108 (1.6) 56 (0.9) <.001
Ventricular arrhythmia requiring treatment 94 (0.7) 57 (0.8) 37 (0.6) .062
Myocardial infarction 63 (0.5) 38 (0.6) 25 (0.4) .16
1 Complication 1384 (10.3) 888 (13.1) 496 (7.5) <.001
Death 193 (1.4) 141 (2.1) 52 (0.8) <.001
Data presented as n (%). VATS, Video-assisted thoracoscopic surgical; ARDS, adult respiratory distress syndrome. *Comparison between open and VATS groups.
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SNC) using the PROC GLIMMIX procedure. ORs are presented to reflect
clinically meaningful absolute decreases of 10%.
To account for the differences in the open and VATS groups in an
additional way, 1:1 propensity matching was performed. First, a logistic
regression model was considered using the approach (open vs VATS) as
the dependent variable and the preoperative subject characteristics from
Table 1 as independent variables, but without FEV1% and DLCO%. A
propensity score was then estimated from this model, and pairs of
VATS and open subjects were matched according to the propensity score.
Most of the pairs had differences in the propensity score of <0.001
(92.9%), and matched pairs were not formed if the propensity score dif-
ference was>0.1. Univariable comparisons between the open and VATS
groups at different ppoFEV1% and ppoDLCO% ranges were then per-
formed with conditional logistic regression to account for the matched
situation.TABLE 3. Multivariate analyses of decreasing ppoFEV1% and
ppoDLCO% as predictors of cardiopulmonary complications
Variable*
Openy (n ¼ 6802) VATSz (n ¼ 6574)
OR (95% CI) P value OR (95% CI) P value
ppoFEV1% 1.170 (1.105-1.238) <.001 1.122 (1.048-1.200) .001
ppoDLCO% 1.099 (1.041-1.159) <.001 1.069 (1.001-1.142) .046
FEV1% 1.161 (1.109-1.216) <.001 1.094 (1.036-1.155) .001
DLCO% 1.095 (1.049-1.143) <.001 1.057 (1.003-1.114) .040
ppo, Predicted postoperative; FEV1%, percentage of predicted forced expiratory
volume in 1 second; DLCO%, percentage of predicted diffusing capacity of the
lung for carbon monoxide; VATS, video-assisted thoracoscopic surgical;OR, odds ra-
tio (associated with absolute 10% decrease); CI, confidence interval. *Separate
models were performed containing either ppoFEV1% and ppoDLCO% or
FEV1% and DLCO%. yAdjusted for significant univariate predictors of cardiopul-
monary complications: age, gender, smoking status, Zubrod score, ASA risk class,
clinical T descriptor, preoperative radiotherapy, coronary artery disease, hyperten-
sion, COPD, and thoracic reoperation. zAdjusted for significant univariate predictors
of cardiopulmonary complications: age, smoking status, Zubrod score, ASA risk
class, coronary artery disease, peripheral vascular disease, COPD, and last creatinine
level.RESULTS
From 2009 to 2011, 18,570 patients underwent
lobectomy for lung cancer (9920 open, 8650 VATS).
Laterality was available for 17,500 patients (94.2%),
FEV1% was available for 17,344 patients (93.4%), and
DLCO% was available for 13,872 patients (74.7%). Our
final patient cohort included 13,376 patients who had
undergone lobectomy for cancer, 6802 (50.9%) who had
undergone open lobectomy, and 6574 (49.1%) who had
undergone VATS lobectomy.
The preoperative characteristics of our cohort are listed
in Table 1. Patients undergoing VATS lobectomy gener-
ally had better performance status (Zubrod score), lower
American Society of Anesthesiologists risk class, less
advanced clinical T and N staging determinants, fewer
medical comorbidities including coronary artery disease,
pulmonary hypertension, chronic obstructive pulmonary
disease, and diabetes, and were less likely to have
received preoperative chemotherapy or radiotherapy. The
mean FEV1% (standard deviation) for the entire cohort
was 81.7%  20.4%, and the mean DCLO% was 73% 
21.7%. The mean ppoFEV1% for the entire cohort was
64.6%  16.7%, and the mean ppoDLCO% was
57.8%  17.6%. Patients undergoing VATS lobectomy22 The Journal of Thoracic and Cardiovascular Surgedemonstrated slightly better pulmonary function
(FEV1%, DLCO%, ppoFEV1%, and ppoDLCO%) than
those undergoing open lobectomy.
The rates of postoperative cardiopulmonary complica-
tions and postoperative mortality in our cohort are listed
in Table 2. Patients undergoing open lobectomy were
more likely to have 1 cardiopulmonary complication
(13.1%) than were patients undergoing VATS lobectomy
(7.5%). Postoperative mortality in the open group was
2.1% and was 0.8% in the VATS group.
In multivariate analyses (Tables 3 and 4), lower
ppoFEV1% and ppoDLCO% were each independent
predictors of an increased incidence of cardiopulmonary
complications and mortality in the open group. In the VATS
group, however, ppoFEV1% was an independent predictor
of complications, but not of mortality, and ppoDLCO%
was an independent predictor of both complications and
mortality. To understand how ppoFEV1% and ppoDLCO%ry c July 2014
TABLE 4. Multivariate analyses of decreasing ppoFEV1% and
ppoDLCO% as predictors of postoperative mortality
Variable*
Openy (n ¼ 6802) VATSz (n ¼ 6574)
OR (95% CI) P value OR (95% CI) P value
ppoFEV1% 1.183 (1.045-1.338) .008 1.029 (0.849-1.248) .77
ppoDLCO% 1.248 (1.102-1.413) <.001 1.310 (1.074-1.598) .008
FEV1% 1.145 (1.038-1.263) .007 1.003 (0.861-1.168) .97
DLCO% 1.188 (1.077-1.309) <.001 1.221 (1.043-1.430) .013
ppo, Predicted postoperative; VATS, video-assisted thoracoscopic surgical; OR, odds
ratio (associated with absolute 10% decrease); CI, confidence interval; FEV1%,
percentage of predicted forced expiratory volume in 1 second; DLCO%, percentage
of predicted diffusing capacity of the lung for carbon monoxide. *Separate models
were performed, containing either ppoFEV1% and ppoDLCO% or FEV1% and
DLCO%. yAdjusted for significant univariate predictors of postoperative mortality:
age, gender, smoking status, Zubrod score, ASA risk class, congestive heart failure,
steroid use, and thoracic reoperation. zAdjusted for significant univariate predictors
of postoperative mortality: age, Zubrod score, ASA risk class, coronary artery dis-
ease, congestive heart failure, and COPD.
TABLE 5. Preoperative variables for 9078 patients in propensity-





(n ¼ 4215) P value
Age (y) 67.2  10.2 67.2  10.3 1.0
Female gender 2246 (53.3) 2246 (53.3) 1.0
Race .98
White 3763 (89.3) 3766 (89.3)
Black 352 (8.4) 345 (8.2)
Asian 92 (2.2) 96 (2.3)
Other 8 (0.2) 8 (0.2)
BMI (kg/m2) 27.6  6.0 27.6  6.3 .89
Smoking .94
Current 1072 (25.4) 1074 (25.5)
Never or past 3143 (74.6) 3140 (74.5)
Zubrod score .99
0 1776 (42.1) 1783 (42.3)
1 2261 (53.6) 2255 (53.5)
2 154 (3.7) 155 (3.7)
3-4 24 (0.6) 22 (0.5)
ASA risk class .84
I-II 631 (15.0) 639 (15.2)
III 3218 (76.3) 3223 (76.5)
IV 366 (8.7) 353 (8.4)
cT descriptor .94
T1 2642 (62.7) 2627 (62.3)
T2 1283 (30.4) 1307 (31.0)
T3 229 (5.4) 222 (5.3)
T4 61 (1.4) 59 (1.4)
cN descriptor .77
N0 3721 (88.3) 3726 (88.4)
N1 327 (7.8) 311 (7.4)
N2 156 (3.7) 169 (4.0)
N3 11 (0.3) 9 (0.2)
Preoperative chemotherapy 264 (6.3) 280 (6.6) .44
Preoperative RT 244 (5.8) 245 (5.8) .96
CAD 939 (22.3) 939 (22.3) 1.0
CHF 116 (2.8) 122 (2.9) .69
PVD 448 (10.6) 448 (10.6) 1.0
CVD 366 (8.7) 353 (8.4) .61
HTN 2658 (63.1) 2610 (61.9) .29
COPD 1542 (36.6) 1527 (36.2) .73
Pulmonary HTN 63 (1.5) 58 (1.4) .90
Diabetes 781 (18.5) 777 (18.4) .91
Last creatinine (mg/dL) 1.0  0.6 1.0  0.6 .78
Last hemoglobin (g/dL) 13.2  1.7 13.2  1.6 .53
Steroid use 140 (3.3) 141 (3.3) .95
General thoracic reoperation 198 (4.7) 193 (4.6) .79
Data presented as mean  standard deviation or n (%). VATS, Video-assisted
thoracoscopic surgical; BMI, body mass index; ASA, American Society of
Anesthesiologists; cT, clinical T; cN, clinical N; RT, radiotherapy; CAD, coronary
artery disease; CHF, congestive heart failure; PVD, peripheral vascular disease;
CVD, cerebrovascular disease; HTN, hypertension; COPD, chronic obstructive
pulmonary disease.
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Sperformed as predictors of complications and mortality
compared with their parent values, FEV1% and
DLCO% were tested in identical multivariate models
(Tables 3 and 4). Compared with their parent values of
FEV1% and DLCO%, ppoFEV1% and ppoDLCO%
appeared to have a similar predictive strength for
postoperative complications and mortality in patients
undergoing open lobectomy and a similar predictive
strength for complications in patients undergoing VATS
lobectomy. For patients undergoing VATS lobectomy,
neither ppoFEV1% nor FEV1% predicted mortality, and
ppoDLCO% demonstrated a stronger association with
mortality (OR, 1.31) compared with its parent DLCO%
parameter (OR, 1.22).
To further explore the relationship between ppoFEV1%
and ppoDLCO% and operative risk, 1:1 propensity match-
ing was used to establish open and VATS lobectomy groups
with balanced preoperative characteristics. Each group
included 4215 patients, and their preoperative characteris-
tics are listed in Table 5. The model resulted in no statisti-
cally significant differences in preoperative variables that
included age, smoking history, performance status, Amer-
ican Society of Anesthesiologists risk class, clinical T and
N descriptors, medical comorbidities, and the use of preop-
erative chemotherapy or radiotherapy. The rates of postop-
erative mortality and cardiopulmonary complications after
open and VATS lobectomy were evaluated at incremental
ranges of ppoFEV1% and ppoDLCO% (Figure 1). Greater
mortality rates were seen in the open than in the VATS
groups at lower ppoFEV1% and ppoDLCO% values
(Figure 1, A and B); however an insufficient number of pa-
tients comprised the ppoFEV1% and ppoDLCO%<30%
groups to reach statistical significance. Similar trends of
greater rates of postoperative complications in the open
versus VATS groups were seen at lower ppoFEV1% ranges,
although these differences were not as pronounced at lowerThe Journal of Thoracic and CppoDLCO% levels (Figure 1, C and D). Similar analyses
using the parent values of FEV1% and DLCO% are
displayed in Figure 2.ardiovascular Surgery c Volume 148, Number 1 23
FIGURE 1. Rates of (A) and (B) postoperative mortality and (C) and (D) cardiopulmonary complications in propensity-matched open and video-assisted
thoracoscopic surgical (VATS) lobectomy groups, stratified by predicted postoperative percentage of predicted forced expiratory volume in 1 second
(ppoFEV1%) and percentage of predicted diffusing capacity of the lung for carbon monoxide (ppoDLCO%). *P<.05.
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SBecause perhapsmore clinicallymeaningful interpretation
of these data could be obtained when considering patients at
PFT values less than a certain threshold (eg,<30%,<40%,
<50%), the rates of postoperative complications and mortal-
ity at varying thresholds for ppoFEV1%, ppoDLCO%,
FEV1%, and DLCO% are listed in Tables E1 to E4. When
considering patients with ppoFEV1% <40%, mortality
was significantly greater in the open group (4.8%) than
the propensity-matched VATS group (0.7%, P ¼ .003).
Likewise, in patients at ppoDLCO%<40%, mortality was
5.2% in the opengroup and2.0% in thematchedVATSgroup
(P ¼ .003). The rate of cardiopulmonary complications was
greater in patients with ppoFEV1% <40% undergoing
open lobectomy (21.9%) than in matched patients
undergoing VATS lobectomy (12.8%, P ¼ .005).
Similar results were seen in the complication rates at
ppoDLCO%<40% for the open group (19.3%) compared
with the matched VATS group (14.6%), although the differ-
ence was not quite as distinct (P ¼ .026).
DISCUSSION
FEV1 and DLCO have been viewed as complementary
physiologic tests for assessing risks related to pulmonary24 The Journal of Thoracic and Cardiovascular Surgeresection. The earliest studies focused on spirometry, and
data from>2000 patients in 3 large series from the 1970s
have demonstrated that a mortality rate of<5% could be
achieved for patients undergoing lobectomy if the preopera-
tive FEV1 was>1.5 L and in patients undergoing pneumo-
nectomy if >2 L.5 A variety of small studies well
summarized by Colice and colleagues3 has demonstrated
increased postoperative morbidity and mortality in patients
with a ppoFEV1% or ppoDLCO%<40%, and these values
have traditionally been considered to represent high surgical
risk. In the 1980s, Ferguson and colleagues6 established the
usefulness of DLCO in predicting operative risk in patients
undergoing pulmonary resection. DLCO assesses the micro-
architecture of the alveolus and is a valuable proxy for alve-
olar gas exchange. ppoDLCO% values of<40% have been
associated with mortality rates as high as 23%,11 and
ppoDLCO% values of<30% have been associated with
postoperative pulmonary complication rates as great as
80%.10 A lowDLCOhas also correlatedwith increased read-
missions to the hospital and poor quality of life after pulmo-
nary resection.22
When abnormalities of FEV1 or DLCO have been
identified preoperatively, it can be useful to estimate thery c July 2014
FIGURE 2. Rates of (A) and (B) postoperative mortality and (C) and (D) cardiopulmonary complications in propensity-matched open and video-assisted
thoracoscopic surgical (VATS) lobectomy groups, stratified by forced expiratory volume in 1 second (FEV1) and diffusing capacity of the lung for carbon
monoxide (DLCO). *P<.05.
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Society guidelines, although published in 2001, have
recommended calculation of the ppoFEV1% and
ppoDLCO% in patients not clearly operable on the basis
of spirometry alone. Also, exercise testing has been
recommended for anyone with a ppoFEV1% or
ppoDLCO%< 40%. According to the British Thoracic
Society, patients with both a ppoFEV1% and ppoDCLO%
<40% have a high operative risk for lobectomy, and
consideration of either sublobar resection or radiotherapy
has been recommended for such patients.5 The American
College of Chest Physicians has recently updated their
guidelines for the preoperative evaluation of patients with
lung cancer and has recommended that both ppoFEV1%
and ppoDLCO% be calculated in all patients being
considered for lung resection.4 Although in the previous
version of the American College of Chest Physicians
guidelines, patients with a ppoFEV1% or ppoDLCO%
<40% were thought to be at increased risk and
consideration for additional workup with cardiopulmonary
exercise testing was recommended for this group, the 2013The Journal of Thoracic and Cguidelines have evolved. Currently, the American College
of Chest Physicians has recommended additional
preoperative risk stratification with a low technology
exercise test (stair climb or shuttle walk test) for patients
whose ppoFEV1% or ppoDLCO% is <60% predicted
but both >30% predicted. A formal cardiopulmonary
exercise test has been recommended for patients with a
ppoFEV1% or ppoDLCO% of<30%.4 The evolution of
these guidelines should facilitate the offering of curative
surgery to patients with more severe abnormalities in lung
function, and such recommendations have been supported
by our multi-institutional data. Any guidelines, however,
must be cautiously interpreted, and preoperative risk
stratification should be performed on an individualized
patient basis. These recommendations, for example, may
not adequately take into account the possible volume reduc-
tion effect that can occur in patients with heterogeneous
emphysema.16
The methods for estimation of postoperative predicted
lung function include radionuclide perfusion scans, quanti-
tative computed tomography, and anatomic calculation byardiovascular Surgery c Volume 148, Number 1 25
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The radionuclide perfusion scan has been the preferred
method for preoperative estimation of lung function after
pneumonectomy because the anatomic method tends to
underestimate the actual measured postoperative values.23
However, for calculation of the predicted postoperative
lung function after lobectomy, substantial equivalency has
been found among the different methods of prediction of
residual postoperative function.24 The anatomic method
has been recommended for estimating lung function
after lobectomy,4,5 and a strong correlation has been
found between the ppoFEV1 calculated by estimating
the segments remaining and the actual measured
postoperative FEV1.21,25 Admittedly, these correlations
will be less accurate in patients with heterogeneous
emphysema.
Our multivariate analyses suggested that ppoFEV1%,
ppoDLCO%, and their parent values of FEV1% and
DLCO% can each be valuable for predicting cardiopulmo-
nary complications and mortality for patients undergoing
open lobectomy. In contrast to a single-institution study in
which FEV1% and DLCO% were not associated with the
incidence of postoperative pulmonary complications in
patients with impaired pulmonary function who underwent
VATS lobectomy,26 our data have suggested that
ppoFEV1%, ppoDLCO%, FEV1%, and DLCO% will be
useful predictors of cardiopulmonary complications after
VATS lobectomy. For the prediction of mortality after
VATS lobectomy, however, we have demonstrated that
ppoFEV1% and FEV1% do not have predictive value.
ppoDLCO% and DLCO% did predict mortality after
VATS lobectomy, and ppoDLCO% performed better
(OR, 1.31) in this capacity than did DLCO% (OR, 1.22).
These results support previous evidence demonstrating
that ppoDLCO% value is a sensitive predictor of post-
operative events,10-12 and its improved performance
compared with other PFT values might have been
amplified in our VATS cohort in which the postoperative
morality events were relatively low.
Thoracoscopic lobectomy has been shown in 2
propensity-matched analyses to be associated with a
lower overall frequency of complications compared
with lobectomy.17,18 Although the differences in these
outcomes were statistically significant in favor of
VATS, they have generally not been dramatically
different. Our data suggest that the benefit of VATS
lobectomy compared with open lobectomy is most
evident in patients with compromised pulmonary
function. Compared with a propensity-matched group of
patients undergoing VATS lobectomy, mortality and
cardiopulmonary complications increased at a greater
rate with decreasing levels of ppoFEV1% and
ppoDLCO% for patients undergoing open lobectomy.
Our findings are in line with those recently reported by26 The Journal of Thoracic and Cardiovascular SurgeCeppa and colleagues,19 who showed that patients
with FEV1% <60% undergoing VATS lobectomy
had a significantly lower frequency of pulmonary
complications than nonmatched patients undergoing
open lobectomy.
The threshold of ppoFEV1% and ppoDLCO% of
<40% was chosen to compare the performance of open
and VATS lobectomy because historically, this threshold
was thought to represent a high risk of postoperative
morbidity and mortality.3 We, and others,4 however,
believe that this inference has not been substantiated in
the current era and that the emergence of minimally
invasive approaches to lobectomy is one of the factors
that have allowed us to expand preoperative risk models
to safely offer resection to patients with compromised
pulmonary function. As an example, the postoperative
complication and mortality rate in the present study after
VATS lobectomy in patients with ppoFEV1% < 40%
was 12.8% and 0.7%, compared with 21.9% and 4.8%
in a propensity-matched open lobectomy cohort,
respectively. Such knowledge will be useful for a
general thoracic practice when considering patients with
compromised pulmonary function for lobectomy and for
informed discussions with patients regarding operative
risk. It can be used side-by-side with other clinical data
that we know will often allow safe pulmonary resection
in many patients with severely reduced pulmonary
function, such as the location of a tumor within a lobe
that has been most severely affected by parenchymal
destruction in a markedly hyperexpanded patient with a
heterogeneous distribution of emphysema.16
Decreased postoperative pain and improved chest wall
mechanics after VATS lobectomy likely translate into
improved pulmonary mechanics and might, at least partially,
account for our results. It is reasonable to speculate that pa-
tients undergoing VATS lobectomy will not only develop
fewer complications, but also might respond better to the
complications that do develop than those undergoing open lo-
bectomy, and this could translate into a mortality benefit.
Although ppoFEV1% is fairly accurate for the prediction
of the postoperative measured FEV1 at 3 to 6 months after
surgery,7,27 it significantly overestimated the FEV1 within
the initial postoperative days when the actual measured
postoperative FEV1 will be about 30% lower than its
predicted value.27,28 It is within these initial days after
surgery that most complications occur, and it has been
shown that FEV1 measured on the first postoperative day
after lobectomy is a better predictor of operative risk than
ppoFEV1.29 Postoperative pulmonary function, including
FEV1, is preserved after VATS comparedwith after thoracot-
omy approaches at early (7 days) and later points (3
months).30,31 This early preservation of pulmonary function
is likely a critical determinant of postoperative morbidity
and mortality.ry c July 2014
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large data set it was based on, the use of a national general
thoracic surgery database, and a propensity-matching
strategy to minimize selection bias. The limitations of
our study include its retrospective nature and the associ-
ated biases inherent to this design. Additionally, data input
into the Society of Thoracic Surgeons database required
that lobectomy and segmentectomy were categorized
together, with segmentectomy accounting for a small frac-
tion of the pulmonary resections. The inclusion of seg-
mentectomy in a cohort into which postoperative lung
function has been calculated according to the segments re-
sected for lobectomy will tend to underestimate the post-
operative predicted lung function. Additionally, although
calculation of predicted postoperative lung function
should ideally account for functional pulmonary heteroge-
neity, previous lung resection, and obstructed or collapsed
lung segments, these variables were not available for
consideration in our study. Furthermore, we could not
accurately account for additional chest wall and dia-
phragm resections or conversion from VATS to an open
procedure.
It is becoming reasonably well accepted that a
VATS approach to lobectomy is associated with less
postoperative morbidity than a thoracotomy approach. Our
results support a role for ppoFEV1% and ppoDLCO%
in the prediction of postoperative risk in patients
undergoing VATS lobectomy and suggest that a minimally
invasive approach could permit safe lobectomy, even for
many patients with the most compromised pulmonary
function.
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Dr David C. Rice (Houston, Tex). This study is important for a
number of reasons. First, it adds to the voluminous body of data
showing that VATS lobectomy, at least for straightforward
resections, is safer for patients than open lobectomy, especially
for high-risk patients. Second, it is the only large study of this
type that has been able to document a decreased operative
mortality associated with VATS. Finally, it has demonstrated
continued increased adoption of VATS lobectomy by surgeons
affiliated with the Society of Thoracic Surgeons. Almost one
half of the lobectomies in this study were performed by VATS,
double the number just 6, 7 years ago.
The study had several obvious limitations, not the least of which
was that apart from the spirometric measurements, we know
nothing of the functional assessments that these high-risk
patients underwent that might have allowed or disallowed their
candidacy for surgery. Thus, the general applicability to an overall
population of patients with lung cancer at high risk is debatable.
You appropriately dealt with the odd clumping of VATS
segmentectomy with lobectomy, and I applaud your use of
propensity analysis. I have 4 questions.
I understand that patients who underwent sleeve lobectomy
were excluded from the analysis, but did you also exclude patients
undergoing more extensive procedures such as bilobectomy, chest
wall resection, diaphragm resection, or redo resections that might
have negatively biased the open group?
Second, the Duke University group published a study last year
that used the same database for an earlier cohort and analyzed by
the same biostatistical group that showed a greater incidence of
pulmonary morbidity but a relatively less overall reduction in
mortality related to VATS. How do you account for the differences
between that study and yours?
Third, it has been shown by several other studies that the
operative outcomes after lobectomy are highly related to center
volume. Is it possible that the centers that performed VATS were
also the high-volume centers and did you or do you plan on
studying hospital volume as a possible contributing factor?
Finally, if the ppoFEV1 and ppoDLCO of <40% were not
necessarily associated with prohibitive morbidity after VATS
lobectomy, at what value should we stop?
I congratulate you on an excellent presentation and thank you
for allowing me to review the report and slides well in advance.
Dr Burt. Thank you, Dr Rice, for reviewing the report and for
your insightful questions.
In terms of your first question, we did exclude patients who
were undergoing sleeve lobectomy and we did exclude patients
who underwent bilobectomy. We included patients who were
undergoing a reoperation; that was about 5.5% of the cases. That
was controlled for in our multivariate analysis and was balanced
in our propensity analysis. Your point on the additional chest28 The Journal of Thoracic and Cardiovascular Surgewall resection and diaphragm resection is a good one, and although
these probably represented a low overall fraction of lobectomies,
they were not controlled for in the present study.
Then your second question is about the report by Drs Ceppa and
Onaitis last year in the Annals of Surgery.What they showed, using
mostly the previous version of the Society of Thoracic Surgeons
database was that patients who underwent open lobectomy had
increased cardiopulmonary complications if their FEV1 was
<60%. Thus, patients whose FEV1 was<60% who underwent
open lobectomy had greater rates of postoperative complications
than a nonmatched VATS comparison group. Their overall rate
of complications was about 22% in the open group and 18% in
the VATS group, greater than our overall complication rate. I did
not show it in the slides, but our overall rate of cardiopulmonary
complications was 13% in the open group and 7% in the VATS
group, which was significantly lower. I believe that this was
probably a function of time. We considered the period from
2009 to 2011, and the previously quoted study was from 2002 to
2009 or 2010, and it is likely that our complication rates have
been decreasing over time.
Your third point is about center volume. As you alluded, it has
been shown that for a variety of operations, higher volume centers
have had lower rates of operative risk, and we did not consider this
specifically in our study. However, I will tell you that I did survey
all the input data from the 186 institutions that contributed to the
Society of Thoracic Surgeons database during the study period,
and no one or several institutions disproportionately contributed
to the number of VATS operations.
Then, your final question is really, I guess, the crux of our
report, which is how should these data be interpreted. It was not
our intention to decide a numeric value for which there is a
prohibitive, or high, or low risk of surgery. That is why I showed
the data in the figure so that practicing thoracic surgeons can
make an informed decision of the risk at different levels of ppo.
As you also alluded, this is only 1 variable in the equation when
evaluating patients, and it is a combination of clinical judgment
and experience and an evaluation of patient frailty and a number
of other patient-related factors that are just as important or more
important than any of the numbers I have shown you. However,
I hope I did convince you that patients with compromised
pulmonary function can undergo VATS lobectomy with relative
safety.
Dr Scott Swanson (Boston, Mass).Bryan, that was an excellent
presentation. You have obviously been well trained. My question
for you is, do you think these data about marginal reserve related
to DLCO is generalizable to other types of marginal reserve,
whether cardiac or age or other evidence of frailty, such that
VATS would be an improvement in those groups as well?
Number 2, you are a practicing cardiothoracic surgeon. How do
you use these data? Do you believe that VATS lobectomy is a
paradigm shift and allows you to perform operations that you
might not have had you only been able to perform open
thoracotomy?
Dr Burt. In terms of your first question, these are multivariate
predictors; thus, it takes into account all the other variables. Others
have shown that if you have something else in addition to a
compromised pulmonary function, such as increased age or
worsening cardiac function, your risk can double. Thus, I thinkry c July 2014
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evaluating a patient.
Regarding your second question about a paradigm shift, I think
so. Obviously, less trauma and better pulmonary recovery
occurs after VATS lobectomy. I believe these data represent an
improvement in the care of patients with lung cancer who would
previously not have been able to undergo lobectomy secondary
to compromised pulmonary function and who now could
potentially be offered VATS lobectomy.
Dr Joel D. Cooper (Philadelphia, Pa). Dr Burt, I enjoyed your
report, and it is obvious that a great deal of work and data mining
went into it. Although I disagree with your conclusion, I think the
most important point is being missed. It is not a question of VATS
versus open. We could argue that all day, and I happen to disagree
with you. What I am mainly concerned about however, are other
issues.
Your abstract read ‘‘predicted postoperative values of<40% of
normal are considered prohibitive for lobectomy owing to high
rates of mortality and cardiopulmonary complications.’’ That
simply is not true, and this is not the first report that has made
that statement. What you are saying is that a preoperative FEV1
of 50% of the predicted value is considered too high a risk for
lobectomy. You do not believe that, do you? The results you
have reported for the open procedures show, overall, a rather
good result. Thus, I am concerned about such a misleading
statement, and my first question is, do you really believe it,
regardless of whether the procedure is to be VATS or open?
Dr Burt. I submit that statement might have been a little
aggressive in the abstract, which I did not actually end up including
in the report. What I do believe and what the American College of
Chest Physicians recommends is that a ppo value of <40%
identifies a patient at high risk, and their national guidelines would
suggest that patients with a ppoFEV1 of<40% deserve additional
workup, possibly cardiopulmonary exercise testing. They have
stated that a ppoFEV1 of<30% is a prohibitive risk and that those
patients should perhaps undergo sublobar resection or stereotactic
body radiotherapy instead of lobectomy. So, I do not believe that a
ppo of<40% is prohibitive risk, but I believe it does identify
patients at very high risk.
If you look at the data, the mortality was 5 times greater among
the>600 matched patients with a ppoFEV1 of<40% undergoing
open compared with VATS lobectomy. To me, that is a pretty
impressive statistic.
Dr Cooper. But with VATS, you report a 5 times greater
mortality when you operate on patients who have a predicted post-
operative FEV1 of 20% to 30% compared with your group ofThe Journal of Thoracic and Cpatients whose predicted postoperative FEV1 was<20%. So, there
are many ways one can interpret or play with the data.
The second point is I do not believe that the prediction of the
postoperative FEV1 is helpful, especially as one goes to lower
and lower values of the FEV1. The patients with the poorest
preoperative FEV1s usually have the most severe emphysema.
In those patients, the actual postoperative FEV1 after lobectomy
usually increases, not diminishes, because of the so-called volume
reduction effect of removing a lobe that has a significant degree of
emphysematous destruction. Therefore, why use the prediction of
the postoperative value in such patients? Returning to my first
point, what you are suggesting is that a patient with an actual
FEV1 of <50% of the predicted value would represent a
prohibitive risk of morbidity and mortality after lobectomy. This
leads to my last and greatest concern. By accepting as your prem-
ise, someone else’s guidelines, especially nonsurgeons’ opinions
as to what does and does not constitute prohibitive risk, we are
abrogating our responsibility as thoracic surgeons. You know as
well as I do that many factors must be considered in selecting
appropriate candidates for lung resection. These include the
severity, pattern, and distribution of the emphysematous changes,
the overall performance status of the patient, how much of the
reduced FEV1 has resulted from airway disease and how much
from emphysema, and so forth. We reported 10 years ago at this
meeting on 21 consecutive patients with a FEV1 <30% who
underwent resection of lung cancer, 18 of the 21 being
lobectomies. None of these patients had died within the first
12 months. Thus, my question is what are we going to do to change
the misconception in the nonthoracic community as to what does
and does not constitute a prohibitive risk of morbidity and
mortality?
Dr Burt. I would like to reply to your first point about the
emphysema. It is clear that the FEV1 is not as accurate in
patients with chronic obstructive pulmonary disease, and 1
limitation of the study was that we could not know which
nonfunctional emphysematous lobes were removed. These
patients perhaps benefited from the lung volume reduction
surgery effect of a lobectomy. So, that is a limitation of the study.
However, the DLCO has been shown, even in patients with
compromised pulmonary function or decreased air flow or
chronic obstructive pulmonary disease, to still predict operative
mortality.
I understand your point. I think we all have to make our own
decisions. I am not suggesting that we follow others’ guidelines,
but I think there is a clear separation between those undergoing
VATS and open lobectomy based on at least these parameters.ardiovascular Surgery c Volume 148, Number 1 29
TABLE E1. Rates of cardiopulmonary complications in propensity-matched open and VATS groups
ppoFEV1% or ppoDLCO%
ppoFEV1% ppoDLCO%
Open VATS P value Open VATS P value
<20 1 (20) 0 (0) 1.0 8 (26.7) 2 (8.3) .16
<30 11 (22) 7 (11.3) .19 39 (21.9) 22 (14.6) .12
<40 68 (21.9) 35 (12.8) .005 133 (19.3) 86 (14.6) .026
<50 171 (20.4) 95 (12.4) <.001 261 (17.6) 170 (12.2) <.001
<60 302 (17.1) 178 (11.2) <.001 373 (14.9) 243 (10.4) <.001
<70 402 (14.4) 254 (10.0) <.001 451 (13.8) 289 (11.5) <.001
<80 477 (13.5) 315 (9.3) <.001 488 (12.9) 327 (8.8) <.001
<90 509 (12.9) 334 (8.5) <.001 505 (12.5) 341 (10.5) <.001
Data presented as n (%). VATS, Video-assisted thoracoscopic surgical; ppo, predicted postoperative; FEV1%, percentage of predicted forced expiratory volume in 1 second;
DLCO%, percentage of predicted diffusing capacity for carbon monoxide.
TABLE E2. Rates of postoperative mortality in propensity-matched open and VATS groups
ppoFEV1% or ppoDLCO%
ppoFEV1% ppoDLCO%
Open VATS P value Open VATS P value
<20 1 (20) 0 (0) 1.0 2 (6.7) 0 (0) .5
<30 5 (10) 2 (3.2) .24 12 (6.7) 4 (2.6) .12
<40 15 (4.8) 2 (0.7) .003 36 (5.2) 12 (2.0) .003
<50 32 (3.8) 7 (0.9) <.001 57 (3.8) 21 (1.5) <.001
<60 53 (3.0) 17 (1.1) <.001 67 (2.7) 25 (1.1) <.001
<70 70 (2.5) 24 (0.9) <.001 77 (2.3) 29 (0.9) <.001
<80 82 (2.3) 27 (0.8) <.001 82 (2.2) 30 (0.8) <.001
<90 87 (2.2) 32 (0.8) <.001 86 (2.1) 32 (0.8) <.001
Data presented as n (%). VATS, Video-assisted thoracoscopic surgical; ppo, predicted postoperative; FEV1%, percentage of predicted forced expiratory volume in 1 second;
DLCO%, percentage of predicted diffusing capacity for carbon monoxide.
TABLE E3. Rates of cardiopulmonary complications in propensity-matched open and VATS groups
ppoFEV1% or ppoDLCO%
FEV1% DLCO%
Open VATS P value Open VATS P value
<20 0 (0) 0 (0) 1.0 3 (27.3) 1 (12.5) .6
<30 2 (28.6) 1 (9.1) .53 17 (28.8) 2 (4.4) .002
<40 12 (19.0) 10 (13.0) .36 47 (22.9) 27 (15.8) .091
<50 61 (23.8) 32 (13.1) .003 123 (21.7) 73 (14.3) .002
<60 132 (21.5) 71 (12.4) <.001 226 (19.0) 150 (13.4) <.001
<70 234 (19.3) 125 (11.3) <.001 326 (16.5) 205 (11.0) <.001
<80 333 (16.6) 204 (11.1) <.001 406 (15.0) 259 (10.0) <.001
<90 426 (14.8) 265 (10.0) <.001 459 (13.8) 297 (9.1) <.001
Data presented as n (%). VATS, Video-assisted thoracoscopic surgical; FEV1%, percentage of predicted forced expiratory volume in 1 second; DLCO%, percentage of predicted
diffusing capacity for carbon monoxide.
TABLE E4. Rates of postoperative mortality in propensity-matched open and VATS groups
ppoFEV1% or ppoDLCO%
FEV1% DLCO%
Open VATS P value Open VATS P value
<20 0 (0) 0 (0) 1.0 1 (9.1) 0 (0) 1.0
<30 2 (28.6) 1 (9.1) .53 5 (8.5) 0 (0) .068
<40 4 (6.3) 2 (2.6) .41 14 (6.8) 4 (2.3) .052
<50 11 (4.3) 2 (0.8) .021 29 (5.1) 7 (1.4) <.001
<60 26 (4.2) 5 (0.9) <.001 54 (4.3) 16 (1.4) <.001
<70 43 (3.5) 11 (1.0) <.001 63 (3.2) 23 (1.2) <.001
<80 58 (2.9) 16 (0.9) <.001 70 (2.6) 26 (1.0) <.001
<90 74 (2.6) 24 (0.9) <.001 76 (2.3) 29 (0.9) <.001
Data presented as n (%). VATS, Video-assisted thoracoscopic surgical; FEV1%, percentage of predicted forced expiratory volume in 1 second; DLCO%, percentage of predicted
diffusing capacity for carbon monoxide.
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